Literature DB >> 9103402

Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer.

A M Codegoni1, M Broggini, M R Pitelli, M Pantarotto, V Torri, C Mangioni, M D'Incalci.   

Abstract

The expression of different genes potentially involved in DNA repair and in cell responses to chemotherapy was evaluated in 33 previously untreated ovarian cancer patients. In biopsies of the same patients the expression of repair genes O6-methylguanine DNA methyltransferase (MGMT), 3-methyladenine DNA glycosylase (MAG), ERCC1, MDR-1, DNA topoisomerase I, DNA topoisomerase IIalpha, and glutathione S-transferase-pi (GST-pi) was assessed by Northern blot analysis. No direct statistical correlation was found between the expression of these genes and the response to chemotherapy (mainly platinum-based with or without doxorubicin and cyclophosphamide). Univariate analysis showed a weak negative correlation (P = 0.037) between the expression of ERCC1 and mortality, whereas no statistically significant correlation was found for other parameters. The MDR-1 gene encoding for the P-glycoprotein P-170 was mostly undetectable in these patients (as assessed by Northern blotting), whereas relatively high levels of MAG and MGMT were found in the majority of patients. A statistically significant correlation was found between the expression of DNA topoisomerase I and the expression of either ERCC1 (P = 0.0026) or GST-pi (P = 0.0279).

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9103402     DOI: 10.1006/gyno.1996.4609

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  12 in total

1.  Alterations in nuclear pore architecture allow cancer cell entry into or exit from drug-resistant dormancy.

Authors:  Yayoi Kinoshita; Tamara Kalir; Jamal Rahaman; Peter Dottino; D Stave Kohtz
Journal:  Am J Pathol       Date:  2011-11-07       Impact factor: 4.307

2.  Mechanisms of resistance to alkylating agents.

Authors:  G Damia; M D'Incalci
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

3.  Predictive value of the ERCC1 expression for treatment response and survival in advanced gastric cancer patients receiving cisplatin-based first-line chemotherapy.

Authors:  Jina Yun; Kyoung-Mee Kim; Seung Tae Kim; Jung-Hoon Kim; Jung A Kim; Jee Hyun Kong; Soo Hyeon Lee; Young-Woong Won; Jong-Mu Sun; Jeeyun Lee; Se Hoon Park; Joon Oh Park; Young Suk Park; Ho Yeong Lim; Won Ki Kang
Journal:  Cancer Res Treat       Date:  2010-06-30       Impact factor: 4.679

Review 4.  Prognostic significance of several biomarkers in epithelial ovarian cancer: a meta-analysis of published studies.

Authors:  Linjuan Xu; Jing Cai; Qiang Yang; Hui Ding; Liying Wu; Tao Li; Zehua Wang
Journal:  J Cancer Res Clin Oncol       Date:  2013-04-18       Impact factor: 4.553

5.  Comparison of ERCC1/XPF genetic variation, mRNA and protein levels in women with advanced stage ovarian cancer treated with intraperitoneal platinum.

Authors:  Julie A Deloia; Nikhil R Bhagwat; Kathleen M Darcy; Mary Strange; Chunquio Tian; Kevin Nuttall; Thomas C Krivak; Laura J Niedernhofer
Journal:  Gynecol Oncol       Date:  2012-05-16       Impact factor: 5.482

6.  Increased ERCC expression correlates with improved outcome of patients treated with cisplatin as an adjuvant therapy for curatively resected gastric cancer.

Authors:  Sun Kyung Baek; Si-Young Kim; Jae Jin Lee; Yoon Wha Kim; Hwi Joong Yoon; Kyung Sam Cho
Journal:  Cancer Res Treat       Date:  2006-02-28       Impact factor: 4.679

7.  Role of MGMT in protecting against cyclophosphamide-induced toxicity in cells and animals.

Authors:  Ryan J Hansen; Susan M Ludeman; Sari J Paikoff; Anthony E Pegg; M Eileen Dolan
Journal:  DNA Repair (Amst)       Date:  2007-05-07

8.  Survival and tumorigenesis in O6-methylguanine DNA methyltransferase-deficient mice following cyclophosphamide exposure.

Authors:  Ramamoorthy Nagasubramanian; Ryan J Hansen; Shannon M Delaney; Mathew M Cherian; Leona D Samson; Scott C Kogan; M Eileen Dolan
Journal:  Mutagenesis       Date:  2008-05-13       Impact factor: 3.000

9.  Peritoneal carcinomatosis from ovarian cancer: chemosensitivity test and tissue markers as predictors of response to chemotherapy.

Authors:  Chiara Arienti; Anna Tesei; Giorgio Maria Verdecchia; Massimo Framarini; Salvatore Virzì; Antonio Grassi; Emanuela Scarpi; Livia Turci; Rosella Silvestrini; Dino Amadori; Wainer Zoli
Journal:  J Transl Med       Date:  2011-06-20       Impact factor: 5.531

10.  Potential predictive markers of chemotherapy resistance in stage III ovarian serous carcinomas.

Authors:  Lovisa Osterberg; Kristina Levan; Karolina Partheen; Ulla Delle; Björn Olsson; Karin Sundfeldt; György Horvath
Journal:  BMC Cancer       Date:  2009-10-18       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.